Genetic analysis of 8;21 chromosomal translocation without AML1 gene involvement in MDS-AML

Abstract

We have investigated a case of acute myelocytic leukaemia derived from myelodysplastic syndrome (MDS-AML) with an 8;21 translocation. In this case the AML1/MTG8 (ETO) fusion transcript was not detected by reverse transcriptase-polymerase chain reaction (RT-PCR), and the rearrangement of the AML1 gene locus was not detected by Southern blot nor pulse field gel electrophoresis (PFGE) analyses using specific probes for the AML1 gene. Fluorescence in-situ hybridization (FISH) study using cosmid probes for 21q22 revealed that the breakpoint of 21q22 was telomeric to the AML1 gene locus and centromeric from D21S259. 351. 3421 loci. This is the first report concerning the t(8:21)(q22:q22) carrying AMLs (de novo AML, MDS AML and therapy-related AML) to show that the breakpoint at 21q22 is located outside the AML1 gene locus. It is also noteworthy that the cell-surface antigen expression pattern of the bone marrow (BM) blasts was changed from CD7+CD2+CD13+CD33+CD19-CD11b+CD14+CD36+ to CD7- CD2- CD13+CD19+CD11b- CD14- CD33+CD34+ CD36-CD56+ during leukaemic progression, and the pattern in leukaemic phase was similar to the characteristic phenotype of de novo AML cases with t(8:21), when the AML1/MTG8 fusion transcripts are always detected by RT-PCR.